PT -期刊文章盟马可Capobianco AU -玛丽安娜Lo再保险盟弗朗西斯卡Sangalli AU -卢西亚Moiola盟Paola Perini AU -保罗·盖洛盟莱安德罗Provinciali AU -莫拉丹尼AU -安娜Repice AU -卢卡Massacesi AU -弗朗西斯科·帕蒂AU -西尔维亚梅西纳盟安东尼奥Bertolotto TI -环磷酰胺脉冲疗法能够减少疾病早期Natalizumab停用后重新激活:从多中心数据库的初步结果。(P3.292) DP - 2015年4月06 TA -神经病首页学PG - P3.292 VI - 84 IP - 14补充4099 - //www.ez-admanager.com/content/84/14_Supplement/P3.292.short 4100 - //www.ez-admanager.com/content/84/14_Supplement/P3.292.full所以Neurology2015 4月06;84 AB -客观评估后环磷酰胺(CTX)的疗效和安全性Natalizumab中止背景Natalizumab停药诱发的复发疾病活动女士:目前没有找到治疗方法能够废除疾病复活。随着更多的复发发生在前6 - 9个月natalizumab中止,有人提出一个简短的洗脱期到下一个治疗诱发疾病的控制活动是必要的。病人和方法。数据收集来自不同意大利女士中心和回顾性评估。结果。数据收集来自32个病人。30个病人至少有12 natalizumab注入;2患者被排除在分析因为只有2 natalizumab注入。 17 out of 30 patients had a maximum period of washout between natalizumab and CTX of 3 months. The mean age at the time of inclusion was 42 years and the mean EDSS was 3.5. The mean number of natalizumab infusions before discontinuation was 28 (range 12-72). The mean follow-up after CTX was 9 months (range 3-20 months) and the mean cumulative dose of CTX was 3731 mg/m2. Only two patients experienced a clinical relapse after 2 and 3 monthly pulses of CTX. No patients had rebound. Only one out of 15 patients showed MRI disease activity. EDSS was stable at the end of follow-up. Only 2 patients developed serious adverse events (SAE): 1 pneumonia and 1 urinary tract infection. Notably, 10/13 patients who had delayed introduction of cyclophosphamide (washout >3 months) had MS disease reactivation with rebound features in 7 patients. Conclusion. These preliminary data show that CTX could be able to reduce disease reactivation after natalizumab discontinuation. This approach must be studied in a large sample of patients for better define the treatment safety and in particular the risk of PML after natalizumab.Disclosure: Dr. Capobianco has received personal compensation for activities with Biogen Idec, Sanofi-Genzyme, Novartis, Merck Serono, and Teva as a consultant and/or speaker. Dr. Lo Re has nothing to disclose. Dr. Sangalli has nothing to disclose. Dr. Moiola has received personal compensation for activities with Biogen Idec, Sanofi-Aventis Pharmaceuticals, and Merck Serono as a speaker, Dr. Perini has nothing to disclose. Dr. Gallo has received personal compensations for activities with Biogen Idec, Novartis, Merk Serono, Bayer Schering, and Genzyme as a speaker and/or consultant. Dr. Provinciali has nothing to disclose. Dr. Danni has nothing to disclose. Dr. Repice has nothing to disclose. Dr. Massacesi has received research support from Biogen Idec and Genzyme. Dr. Patti has received personal compensations for activities with Merck Serono, Bayer Schering Pharma, and Dompé Biotec. Dr. Messina has nothing to disclose. Dr. Bertolotto has received personal compensation for activities with Biogen Idec, Biogen Dompè, Merck Serono, Farmades, Novartis, and Aventis Pharmaceuticals as a speaker and/or consultant.Tuesday, April 21 2015, 2:00 pm-6:30 pm